Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion
- PMID: 9766568
- DOI: 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9
Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion
Abstract
Aberrant expression or activity of the epidermal growth factor (EGF) receptor family of tyrosine kinases has been associated with tumor progression and an invasive phenotype. In this study, we utilized 4 ovarian cancer cell lines, OVCA 432, DOV 13, OVEA6 and OVCA 429, to determine the effects of EGF on the regulation of proteolytic enzymes and their inhibitors, cellular migration and in vitro invasion. Induction of urinary-type plasminogen activator (u-PA) activity and tissue inhibitor of matrix metalloproteinase (TIMP)-1 was observed in all 4 cell lines. OVCA 432 cells showed strong PAI-1 induction; however, the other 3 lines displayed substantial baseline PAI-1 expression that was not induced by EGF. EGF-dependent stimulation of migration and induction of matrix metalloproteinase (MMP)-9 (gelatinase B) was observed in OVEA6 and OVCA 429 cells only. Upon EGF receptor activation, DOV 13, OVEA6 and OVCA 429 cells were induced to invade through an artificial basement membrane (Matrigel); however, no invasion was detected in OVCA 432 cells. Cell lines displaying induction of migration and MMP-9 (OVEA6 and OVCA 429) demonstrated robust EGF-induced invasion (5- to 20-fold), and cell invasion was substantially reduced in the presence of anti-catalytic MMP-9 antibody. Addition of anti-catalytic u-PA antibody inhibited the modest (<2-fold) EGF-induced invasion in a cell line that did not express MMP-9 (DOV 13) and in OVEA6 cells that displayed the highest baseline u-PA activity. Together, our findings indicate that multiple proteinases are important in ovarian cell invasion and implicate EGF induction of MMP-9 and migration as key components of more aggressive ligand-induced invasion.
Similar articles
-
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.Gynecol Oncol. 2000 Nov;79(2):256-63. doi: 10.1006/gyno.2000.5944. Gynecol Oncol. 2000. PMID: 11063654
-
Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.Clin Exp Metastasis. 1999;17(7):631-9. doi: 10.1023/a:1006751016860. Clin Exp Metastasis. 1999. PMID: 10845563
-
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.Cancer Res. 2001 Mar 1;61(5):1855-61. Cancer Res. 2001. PMID: 11280738
-
Collagen induced MMP-2 activation in human breast cancer.Breast Cancer Res Treat. 1994;31(2-3):357-70. doi: 10.1007/BF00666168. Breast Cancer Res Treat. 1994. PMID: 7881112 Review.
-
The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.Int J Oncol. 1998 Mar;12(3):569-76. doi: 10.3892/ijo.12.3.569. Int J Oncol. 1998. PMID: 9472094 Review.
Cited by
-
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.World J Gastroenterol. 2005 Mar 7;11(9):1251-66. doi: 10.3748/wjg.v11.i9.1251. World J Gastroenterol. 2005. PMID: 15761961 Free PMC article. Review.
-
Characteristics of Selected Adipokines in Ascites and Blood of Ovarian Cancer Patients.Cancers (Basel). 2021 Sep 20;13(18):4702. doi: 10.3390/cancers13184702. Cancers (Basel). 2021. PMID: 34572929 Free PMC article. Review.
-
Activated epidermal growth factor receptor in ovarian cancer.Cancer Treat Res. 2009;149:203-26. doi: 10.1007/978-0-387-98094-2_10. Cancer Treat Res. 2009. PMID: 19763438 Free PMC article. Review. No abstract available.
-
The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.Neoplasia. 2009 Nov;11(11):1208-15. doi: 10.1593/neo.09942. Neoplasia. 2009. PMID: 19881956 Free PMC article.
-
Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells.Br J Cancer. 2004 Dec 13;91(12):2042-7. doi: 10.1038/sj.bjc.6602254. Br J Cancer. 2004. Retraction in: Br J Cancer. 2021 May;124(10):1748. doi: 10.1038/s41416-021-01322-z. PMID: 15599381 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous